Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Biogen

Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data?

Biogen Inc. (NASDAQ:BIIB) stock traded higher after Novo Nordisk A/S (NYSE:NVO) released disappointing topline results from the 2-year primary analysis of Evoke and Evoke+ phase 3 trials in early-stage symptomatic Alzheimer's disease.

Benzinga

Biogen Stock: Is Wall Street Bullish or Bearish?

Despite Biogen's underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

Biogen's Immunology Pipeline Has Long-Term Potential: Analyst

On Friday, Biogen Inc. (NASDAQ:BIIB) and Vanqua Bio announced a license agreement granting Biogen exclusive worldwide rights to Vanqua's preclinical, oral C5aR1 antagonist. The agreement strengthens Biogen's immunology.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

What to Expect From Biogen’s Q3 2025 Earnings Report

Biogen is slated to release its fiscal third-quarter earnings later this month, and analysts are expecting its earnings to drop in the single-digit range.

Barchart

Biogen Faces FDA Setback On High-Dose Nusinersen Filing For Spinal Muscular Atrophy

On Tuesday, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for Biogen Inc.’s (NASDAQ: BIIB) supplemental New Drug Application (sNDA) for the high-dose regimen of nusinersen for the treatment of spinal muscular atrophy (SMA).

Benzinga

This Biogen Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga

Biogen's $85 Million Deal Could Change How Patients Get Spinraza Treatment

Biogen Inc. (NASDAQ:BIIB) on Thursday agreed to acquire Massachusetts-based Alcyone Therapeutics for $85 million.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Is Biogen Stock Underperforming the Nasdaq?

Although Biogen has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy

The U.S. Food and Drug Administration (FDA) stated on Thursday that it is requiring an additional MRI scan for Alzheimer's patients receiving Leqembi (lecanemab), citing safety concerns over a rare but potentially fatal side effect.

Benzinga

Biogen Stock: Analyst Estimates & Ratings

Biogen has lagged the broader market over the past year, yet analysts maintain a cautiously optimistic outlook on the stock’s future performance.

Barchart

How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment

Biogen Inc. (NASDAQ:BIIB) CEO Chris Viehbacher said a successful Alzheimer’s trial for Novo Nordisk A/S’ (NYSE:NVO) weight-loss drug wouldn’t threaten his company’s treatment but could instead open the door to combining therapies for stronger results.

Benzinga

Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% year over year, beating the analyst consensus of $4.06.

Benzinga

Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing

Biogen Inc. (NASDAQ:BIIB) said on Monday that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP).

Benzinga

Here's What to Expect From Biogen's Next Earnings Report

Biogen is expected to release its fiscal second-quarter earnings later this month, and analysts project a double-digit profit decline.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Earnings Preview: What To Expect From Biogen's Report

Biogen is poised to announce its first-quarter results next month, and analysts predict a single-digit dip in the company’s bottom-line figure.

The Independent UK

European regulators OK Alzheimer's treatment Leqembi after initial doubts

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected the drug last summer

Barchart

Analysts Love These 2 Growth Stocks That Have Over 200% Upside Potential

Wall Street expects both of these biotech stocks to soar over 200% in the next 12 months.

Barchart

How Is Biogen's Stock Performance Compared to Other Biotech Stocks?

Despite Biogen's underperformance compared to other biotech stocks over the past year, analysts remain moderately optimistic about its future prospects.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Biogen Stock Outlook: Is Wall Street Bullish or Bearish?

Biogen has lagged well behind the broader market over the past year, yet analysts maintain a fairly optimistic outlook on its future performance.

Barchart

2 ‘Strong Buy’ Stocks Under $10 Set to Surge as Much as 331%

These biotech companies are poised for significant long-term growth. However, there are risks.

MarketBeat

Biogen Stock Is Mutating Into a Value Play

Biogen shares have fallen over 70% from its highs nearly 12-years ago, but value investors should take a look at its metrics of just 12.4 P/E and P/B of 1.2X

Barchart

Stocks Settle Mixed as Chip Stock Strength Lifts the Nasdaq

The S&P 500 Index ($SPX ) (SPY ) Wednesday closed down -0.27%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.50%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.12%. March E-mini S&P futures (ESH25 ) are down by -0.29%, and March E-mini Nasdaq...

Barchart

Stocks Tumble as Sticky US Inflation Keeps Fed on Hold

The S&P 500 Index ($SPX ) (SPY ) today is down -0.50%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.63%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.32%. March E-mini S&P futures (ESH25 ) are down by -0.48%, and March E-mini Nasdaq...

Barchart

Stocks Sink and Bond Yields Spike on Strong CPI

The S&P 500 Index ($SPX ) (SPY ) today is down -0.91%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.92%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.89%. March E-mini S&P futures (ESH25 ) are down by -0.87%, and March E-mini Nasdaq...

Barchart

Biogen's Quarterly Earnings Preview: What You Need to Know

Biogen is scheduled to release its fourth-quarter earnings next month, and analysts are forecasting a double-digit increase in its bottom line.

1 2 3 4 5

People

Powell

513 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.